The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19
A Non-interventional, Prospective, Cross-sectional Study of the Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Sars-Cov-2
Hellenic Institute for the Study of Sepsis
345 participants
Dec 10, 2024
OBSERVATIONAL
Conditions
Summary
More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19. The overall concept underpinning "POINT" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous, current, and future SARS-CoV-2 variants in vaccinated and unvaccinated people, and NCDs, ii) identify robust biomarkers and build predictive tools that help early identification and management of risk of NCDs, and iii) develop guidelines and recommendations for all parts of the healthcare value chain, allowing best prevention and care acknowledging vulnerability. The investigators will focus on the NCDs affecting pulmonary, cardiovascular and renal systems.
Eligibility
Inclusion Criteria12
- Group A (comparators)
- Adults (18 years or more) of both genders
- Negative history of acute COVID-19
- Group B (patients with ΝΟ dysfunction)
- Adults (18 years or more) of both genders
- History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
- Absence of any current overt organ dysfunction
- Absence of signs of any organ dysfunction during acute COVID-19
- Group C (patients with dysfunctions)
- Adults (18 years or more) of both genders
- History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
- Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19
Exclusion Criteria19
- Group A (comparators)
- Any other co-existing disorder generating clinical symptoms
- Failure to thrive according to the attending physicians
- Pregnancy or lactation
- Group B (patients with ΝΟ dysfunction)
- Any other co-existing disorder generating clinical symptoms
- Failure to thrive according to the attending physicians
- Pregnancy or lactation
- Group C (patients with dysfunctions)
- Any other co-existing disorder generating clinical symptoms
- Medical history of any of:
- stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria
- pulmonary fibrosis or pulmonary hypertension
- stage IV solid tumour malignancy under chemotherapy or radiotherapy
- systemic sclerosis
- congestive heart failure
- stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
- Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians
- Pregnancy or lactation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood sampling for proteomics and transcriptomics, suPAR measurement \& isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \& urea
Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06608849